Published in J Clin Oncol on September 03, 2013
Optimal management of clinical stage I testis cancer: one size does not fit all. J Clin Oncol (2013) 0.90
Controversies in the management of clinical stage I testicular seminoma. Cent European J Urol (2016) 0.80
Pediatric and Adolescent Extracranial Germ Cell Tumors: The Road to Collaboration. J Clin Oncol (2015) 0.79
Testicular cancer: Optimal management of stage I seminoma in 2015. Nat Rev Urol (2015) 0.78
Surveillance for patients with clinical stage I nonseminomatous testicular germ cell tumors. World J Urol (2014) 0.77
A refined risk stratification scheme for clinical stage 1 NSGCT based on evaluation of both embryonal predominance and lymphovascular invasion. Ann Oncol (2015) 0.75
Best treatment option for clinical stage I seminoma patients. Cent European J Urol (2016) 0.75
The Sound of Silence: A Proxy for Platinum Toxicity. J Clin Oncol (2016) 0.75
Management of stage I testicular germ cell tumours. Nat Rev Urol (2016) 0.75
Reimbursements and frequency of tests in privately insured testicular cancer patients in the United States: Implications to national guidelines. Urol Ann (2017) 0.75
Outcomes of surveillance versus adjuvant chemotherapy for patients with stage IA and IB nonseminomatous testicular germ cell tumors. World J Urol (2016) 0.75
Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry. World J Urol (2016) 0.75
Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med (2011) 27.58
Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med (2012) 20.79
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med (2015) 12.74
Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med (2008) 11.86
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet (2002) 10.17
Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial. Lancet (2011) 8.81
Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med (2012) 8.64
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol (2009) 8.16
Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA (2010) 5.78
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol (2008) 5.50
Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol (2010) 5.44
Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol (2005) 4.99
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol (2013) 4.91
Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med (2008) 4.71
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol (2010) 4.61
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer (2012) 4.29
Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol (2012) 4.14
Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol (2009) 4.07
Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol (2009) 3.69
Fluoxetine versus placebo in advanced cancer outpatients: a double-blinded trial of the Hoosier Oncology Group. J Clin Oncol (2003) 3.58
Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol (2008) 3.53
Aflibercept versus placebo in combination with docetaxel and prednisone for treatment of men with metastatic castration-resistant prostate cancer (VENICE): a phase 3, double-blind randomised trial. Lancet Oncol (2013) 3.45
HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol (2009) 3.37
External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol (2013) 3.19
Docetaxel-based chemotherapy in elderly patients (age 75 and older) with castration-resistant prostate cancer. Eur Urol (2008) 3.06
Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med (2010) 2.97
The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer (2008) 2.91
Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol (2008) 2.88
Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with first-line chemotherapy with or without cetuximab. J Clin Oncol (2012) 2.86
Conditional survival of patients with metastatic renal-cell carcinoma treated with VEGF-targeted therapy: a population-based study. Lancet Oncol (2012) 2.84
The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer (2004) 2.82
The impact of cytoreductive nephrectomy on survival of patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor targeted therapy. J Urol (2010) 2.73
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol (2009) 2.63
Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res (2006) 2.61
Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. J Clin Oncol (2013) 2.52
Impact of a multi-disciplinary patient education session on accrual to a difficult clinical trial: the Toronto experience with the surgical prostatectomy versus interstitial radiation intervention trial. J Clin Oncol (2006) 2.50
Prostate cancer screening: Canadian guidelines 2011. Can Urol Assoc J (2011) 2.50
POU5F1 (OCT3/4) identifies cells with pluripotent potential in human germ cell tumors. Cancer Res (2003) 2.45
Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol (2011) 2.45
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer (2010) 2.43
NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40
Role of P53 and MDM2 in treatment response of human germ cell tumors. J Clin Oncol (2002) 2.36
Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983. J Clin Oncol (2012) 2.36
Phase I and pharmacokinetic study of pemetrexed administered every 3 weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol (2006) 2.35
Postchemotherapy retroperitoneal lymph node dissection in advanced testicular cancer: radical or modified template resection. Eur Urol (2008) 2.34
Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol (2009) 2.32
Clinical nodal staging scores for bladder cancer: a proposal for preoperative risk assessment. Eur Urol (2011) 2.31
A systematic review of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol (2012) 2.31
Alterations in the serum glycome due to metastatic prostate cancer. J Proteome Res (2007) 2.30
Screening for prostate cancer with prostate-specific antigen testing: American Society of Clinical Oncology Provisional Clinical Opinion. J Clin Oncol (2012) 2.28
Genome-wide linkage screen for testicular germ cell tumour susceptibility loci. Hum Mol Genet (2006) 2.23
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol (2007) 2.20
HIV-related lung cancer in the era of highly active antiretroviral therapy. AIDS (2003) 2.15
Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res (2010) 2.15
Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol (2013) 2.14
An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. Blood (2007) 2.14
American Society of Clinical Oncology Clinical Practice Guideline on uses of serum tumor markers in adult males with germ cell tumors. J Clin Oncol (2010) 2.14
Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol (2009) 2.11
Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol (2011) 2.10
Resection of the inferior vena cava without reconstruction for urologic malignancies. Urology (2009) 2.08
Randomized trial comparing two fractionation schedules for patients with localized prostate cancer. J Clin Oncol (2005) 2.06
Utility of serum tumor markers during surveillance for stage I seminoma. Cancer (2012) 2.05
The use of conformal radiotherapy and the selection of radiation dose in T1 or T2 low or intermediate risk prostate cancer - a systematic review. Radiother Oncol (2002) 2.04
Information needs of men on androgen deprivation therapy. BJU Int (2011) 2.02
Surgery for metastatic urothelial carcinoma with curative intent: the German experience (AUO AB 30/05). Eur Urol (2008) 2.02
Inverse relationship between biochemical outcome and acute toxicity after image-guided radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys (2011) 2.00
Null association between histology of first and second primary malignancies in men with bilateral testicular germ cell tumors. Am J Epidemiol (2013) 2.00
Follow-up guidelines after radical or partial nephrectomy for localized and locally advanced renal cell carcinoma. Can Urol Assoc J (2009) 2.00
EAU guidelines on testicular cancer: 2011 update. Eur Urol (2011) 1.96
Multiparameter flow cytometry in the differential diagnosis of aberrant T-cell clones of unclear significance. Leuk Lymphoma (2014) 1.94
Predictive model for survival in patients with advanced cancer. J Clin Oncol (2008) 1.93
Adjuvant cisplatin plus methotrexate versus methotrexate, vinblastine, epirubicin, and cisplatin in locally advanced bladder cancer: results of a randomized, multicenter, phase III trial (AUO-AB 05/95). J Clin Oncol (2005) 1.93
Development and external validation of an extended 10-core biopsy nomogram. Eur Urol (2006) 1.90
Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol (2010) 1.87
NCCN clinical practice guidelines in oncology: testicular cancer. J Natl Compr Canc Netw (2009) 1.86
Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL-positive leukemias identified by a proteomics approach. Blood (2006) 1.85
Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival. J Urol (2007) 1.84
Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials. BJU Int (2011) 1.83
Long-term follow-up of Cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol (2009) 1.82
Treatment of penile strangulation caused by constricting devices. Urology (2002) 1.81
Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res (2011) 1.80
Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol (2011) 1.78
Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer (2003) 1.78
Management of disseminated nonseminomatous germ cell tumors with risk-based chemotherapy followed by response-guided postchemotherapy surgery. J Clin Oncol (2009) 1.78